OBJECTIVE: To comprehensively evaluate sodium aescinate for injection from effectiveness

safety

economy

innovation

suitability and accessibility. METHODS: PubMed

the Cochrane Library

Embase

CBM

CNKI

Wanfang Data and WebCRD were systematically retrieved. The rapid health technology assessment（HTA） was used to analyze the effectiveness

safety and economy of sodium aescinate for injection. National Medical Products Administration

Center for Drug Evaluation of National Medical Products Administration and other professional websites

pharmacopoeia and drug instructions of various countries were retrieved to analyze the innovation

suitability and accessibility of sodium aescinate for injection. RESULTS:（1） In terms of effectiveness and safety

the study population included cerebral edema induced by cerebral hemorrhage

cerebral edema induced by cerebral ischemia

swelling induced by surgery and swelling induced by trauma. The study protocol was sodium aescinate for injection versus mannitol

sodium aescinate for injection versus other positive drugs

sodium aescinate for injection versus blank control

sodium aescinate for injection combined with mannitol versus mannitol

sodium aescinate for injection combined with edaravone versus edaravone

sodium aescinate for injection combined with edaravone versus sodium aescinate for injection

sodium aescinate for injection combined with edaravone versus blank control

the study group and the control group were given routine treatment. Sodium aescinate for injection alone or in combination with positive drugs such as mannitol could significantly improve the treatment efficiency and reduce the incidence of adverse drug reactions.（2） In terms of economics

the application of sodium aescinate for injection combined with mannitol in trauma-induced swelling had the best incremental cost-effectiveness ratio

and the incremental cost-effectiveness ratio in patients with cerebral infarction was inferior to low molecular weight heparin sodium. Sodium aescinate for injection was the class B drug under medical insurance

which had limitations on reimbursement.（3） In terms of innovation

sodium aescinate for injection had two patents in analysis and detection methods and preparation methods.（4） In terms of suitability

the quality standard of sodium aescinate for injection was the national standard

and the injection dosage form had a certain influence on the suitability of drug use.（5） In terms of accessibility

the registered production enterprises of sodium aescinate for injection were located in 11 provinces and municipalities directly under the central government

and the supply of sodium aescinate for injection was well accessible. CONCLUSIONS: The clinical effectiveness and safety of sodium aescinate for injection in patients with cerebral edema induced by hemorrhagic stroke

cerebral edema induced by ischemic stroke

swelling induced by surgery and swelling of traumatic body are significant. The economy of single drug in patients with cerebral edema induced by ischemic stroke and swelling induced by trauma is medium. There are no economic studies on the use of sodium aescinate for injection in patients with surgical swelling.